Related Experiment Videos
Clinical effectiveness of pneumococcal vaccine. Meta-analysis.
B G Hutchison1, A D Oxman, H S Shannon
1Department of Family Medicine, McMaster University in Hamilton, Ont. hutchb@fhs.mcmaster.ca
Canadian Family Physician Medecin De Famille Canadien
|November 30, 1999
Summary
Pneumococcal polysaccharide vaccine significantly reduces the risk of systemic pneumococcal infections by 83% for vaccine-type strains and 73% overall. The vaccine
Area of Science:
- Infectious Diseases
- Vaccinology
- Public Health
Background:
- Pneumococcal infections pose a significant global health burden, particularly in adults.
- Pneumococcal polysaccharide vaccine (PPSV) is widely used, but its clinical effectiveness requires ongoing evaluation.
Purpose of the Study:
- To determine the clinical effectiveness of pneumococcal vaccines in adults.
- To synthesize evidence from randomized and quasi-randomized controlled trials.
Main Methods:
- Comprehensive literature search of MEDLINE, EMBASE, and SCISEARCH databases.
- Inclusion of 13 randomized or quasi-randomized controlled trials involving over 65,000 patients.
- Meta-analysis of vaccine efficacy for various clinical outcomes.
Main Results:
- Vaccine efficacy against vaccine-type systemic pneumococcal infection estimated at 83%.
- Vaccine efficacy against all systemic pneumococcal infections estimated at 73%.
- No significant difference in efficacy observed across different age groups or in individuals with chronic diseases.
Conclusions:
- Pneumococcal polysaccharide vaccine is highly effective in preventing systemic pneumococcal infections.
- The vaccine demonstrates consistent efficacy across diverse adult populations, including the elderly and those with comorbidities.
- Evidence supports the continued use of PPSV for reducing pneumococcal disease burden.